Trials / Recruiting
RecruitingNCT05070403
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Phase 2 Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Afatinib 40 MG | Participants will receive 40 mg Afatinib, once daily. |
Timeline
- Start date
- 2021-10-01
- Primary completion
- 2027-02-01
- Completion
- 2028-03-01
- First posted
- 2021-10-07
- Last updated
- 2026-04-01
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05070403. Inclusion in this directory is not an endorsement.